We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Removing Plasmids Eliminates Antibiotic Resistance

By Biotechdaily staff writers
Posted on 22 Nov 2004
Researchers have treated antibiotic-resistant bacteria with the drug apramycin to inhibit and ultimately remove the plasmids responsible for acquisition of the antibiotic resistance.

Plasmids are bits of extra-chromosomal DNA that are exchanged when bacteria interact. More...
Among the genes carried on plasmids are those responsible for antibiotic resistance. Investigators at the University of Illinois (Urbana-Champaign, USA) selected apramycin, an aminoglycoside antibiotic with bactericidal activity against most Gram-negative bacteria, after testing numerous other potentially useful molecules. They reported in the November 5, 2004, online edition of the Journal of the American Chemical Society that the positively charged apramycin bound to negatively charged plasmid-encoded RNA. This binding inhibited the activity of proteins that trigger plasmid reproduction.

Apramycin was used to treat bacterial cultures that were grown for 250 generations. By the end of this period, plasmids had been eliminated, and the culture had lost its antibiotic resistance.

"This is the first demonstration of a mechanistic-based approach to systematically eliminate the plasmids,” said senior author Dr. Paul J. Hergenrother, professor of chemistry at the University of Illinois. "Standard antibiotics target the cell wall, but as resistance to antibiotics emerges, there needs to be other targets. We validated that plasmids are a new target for antibiotics.”




Related Links:
University of Illinois

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Clinical Informatics Platform
CLARION™
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.